Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+5Founders
Product
Problem
Current cancer screening methods often rely on invasive procedures, imaging, or single-biomarker blood tests that lack sufficient sensitivity for detecting cancer at its earliest, most treatable stages. Delayed diagnosis reduces treatment options and worsens patient outcomes.
Solution
Freenome offers an early cancer detection platform that analyzes a standard blood draw using multiomics technology—integrating genomics, epigenomics, proteomics, and metabolomics data. Advanced artificial intelligence models interpret these complex molecular signatures to identify the presence of cancer before symptoms appear. The approach is designed to be minimally invasive, scalable, and applicable across multiple cancer types. Clinical programs validate the test’s performance and support regulatory pathways, aiming to provide clinicians with a reliable screening tool that can be incorporated into routine preventive care.
Target Audience
Primary customers are healthcare providers, including primary care physicians and health systems, seeking a blood-based screening test for early detection of multiple cancer types.
Features
- Multiomics profiling of blood samples to capture a comprehensive molecular view of disease
- AI-driven algorithms that combine genomic, epigenomic, proteomic, and metabolic data for cancer detection
- Non-invasive testing requiring only a standard blood draw, facilitating easy integration into existing workflows
- Ongoing clinical trials and validation studies to assess sensitivity, specificity, and utility across diverse populations
- Cloud-based data processing pipeline ensuring rapid analysis and secure handling of patient information